Plasma circulating tumor dna levels for the monitoring of melanoma patients: landscape of available technologies and clinical applications

HIGHLIGHTS

• who: Benoit Busser and colleagues from the Biochemistry Pharmacology and Toxicology Department, Grenoble University Hospital, Grenoble, France have published the research: Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications, in the Journal: BioMed Research International of 11/08/2016
• future: There is a reason to believe that ctDNA will play the unhoped-for role of the currently missing gold-standard blood-based biomarker for the monitoring of melanoma in the near future.

SUMMARY

This minimally invasive method to access cancer-derived . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.